A comprehensive review on the use of nanosecond pulsed electric fields in cancer therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Microbial Inactivation Methods · Pulsed Power Technology Applications · Plasma Applications and Diagnostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Nanosecond pulsed electric field (nspef): opening the biotechnological pandora's box10.3390/ijms23116158 ↗
2. Nanosecond pulsed electric field induced cytoskeleton, nuclear membrane and telomere damage adversely impact cell survival10.1016/j.bioelechem.2011.06.002 ↗
3. Nanosecond pulsed electric field (nsPEF) and vaccines: a novel technique for the inactivation of SARS-CoV-2 and other viruses?10.1080/07853890.2022.2087898 ↗
4. Nanosecond bacteria inactivation realized by locally enhanced electric field treatment10.1038/s44221-022-00003-2 ↗
5. Nanosecond electron pulses in the analytical electron microscopy of a fast irreversible chemical reaction10.1038/s41467-019-11669-w ↗
6. Charge and exciton dynamics of oleds under high voltage nanosecond pulse: towards injection lasing10.1038/s41467-020-18094-4 ↗
7. High-power nanosecond pulse generators with improved reliability by adopting auxiliary triggering topology10.1109/TPEL.2019.2922360 ↗
8. Improved auxiliary triggering topology for high-power nanosecond pulse generators based on avalanche transistors10.1109/TPEL.2021.3087732 ↗
9. The physics of lightning10.1016/j.physrep.2013.09.004 ↗
10. Triboemission of hydrocarbon molecules from diamond-like carbon friction interface induces atomic-scale wear10.1126/sciadv.aax9301 ↗
11. Triboelectric microplasma powered by mechanical stimuli10.1038/s41467-018-06198-x ↗
12. Self-powered electrostatic tweezer for adaptive object manipulation10.1016/j.device.2024.100465 ↗
13. On the origin of contact-electrification10.1016/j.mattod.2019.05.016 ↗
14. New advances in treatment of skin malignant tumors with nanosecond pulsed electric field: a literature review10.1016/j.bioelechem.2023.108366 ↗
15. A nanosecond pulsed electric field (nsPEF) can affect membrane permeabilization and cellular viability in a 3D spheroids tumor model10.1016/j.bioelechem.2021.107839 ↗
16. Triboelectric nanogenerators for therapeutic electrical stimulation
17. Recent advances in high-performance triboelectric nanogenerators10.1007/s12274-023-5660-8 ↗
18. Leveraging triboelectric nanogenerators for bioengineering10.1016/j.matt.2021.01.006 ↗
19. Sign-to-speech translation using machinelearning-assisted stretchable sensor arrays10.1038/s41928-020-0428-6 ↗
20. Transcutaneous ultrasound energy harvesting using capacitive triboelectric technology10.1126/science.aan3997 ↗
21. Licciulli
22. Artificial tactile perception smart finger for material identification based on triboelectric sensing10.1126/sciadv.abq2521 ↗
23. Advances in wearable respiration sensors
24. Chemical warfare agents decontamination via air mircoplasma excited by a triboelectric nanogenerator10.1016/j.nanoen.2022.106992 ↗
25. Triboelectric nanogenerator: a foundation of the energy for the new era
26. A self-powered intracardiac pacemaker in swine model10.1038/s41467-023-44510-6 ↗
27. Triboelectric nanogenerators10.1038/s43586-023-00220-3 ↗
28. Dual-function of baicalin in nsPEFs-treated hepatocytes and hepatocellular carcinoma cells for different death pathway and mitochondrial response10.7150/ijms.34876 ↗
29. Recent progress in pulsed electric field ablation for liver cancer10.3748/wjg.v26.i24.3421 ↗
30. Induction of apoptosis of liver cancer cells by nanosecond pulsed electric fields (nsPEFs)10.1007/s12032-016-0882-1 ↗
31. In-vitro bipolar nano- and microsecond electro-pulse bursts for irreversible electroporation therapies10.1016/j.bioelechem.2014.07.010 ↗
32. Power management and effective energy storage of pulsed output from triboelectric nanogenerator10.1016/j.nanoen.2019.04.096 ↗
33. A highly shape-adaptive, stretchable design based on conductive liquid for energy harvesting and self-powered biomechanical monitoring10.1126/sciadv.1501624 ↗
34. Semiconductor contact-electrification-dominated tribovoltaic effect for ultrahigh power generation
35. Tribovoltaic effect: origin, interface, characteristic, mechanism & application
36. A constant current triboelectric nanogenerator arising from electrostatic breakdown
37. Application of pulsed electric fields to cancer therapy10.1089/bioe.2018.0001 ↗
38. A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights10.2478/raon-2023-0044 ↗
39. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)10.1186/1756-6649-9-1 ↗
40. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors10.1073/pnas.0702916104 ↗
41. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials10.1200/JCO.1999.17.8.2572 ↗
42. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma10.1056/NEJMoa043330 ↗
43. Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors10.1016/j.soncn.2018.03.005 ↗
44. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial10.1001/jama.2015.16669 ↗
45. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial10.1001/jama.2017.18718 ↗
46. Lung cancer statistics10.1007/978-3-319-24223-1_1 ↗
47. STELLAR – a phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma10.1016/S1556-0864(16)30322-7 ↗
48. Gl
49. STELLAR: final results of a phase 2 trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma. [abstract]. VIII641. ESMO, Oct 201810.1016/j.jtho.2018.08.416 ↗
50. Pless
51. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy10.1200/JCO.22.02546 ↗
52. Leal · Lancet Oncol. · 2023 · 24 · 100210.1016/S1470-2045(23)00344-3 ↗
53. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo10.1002/ijc.30406 ↗
54. Tumor treating fields for ovarian aarcinoma: a modeling study
55. Safety of tumour treating fields delivery to the torso: meta analysis from TTFields clinical trials10.1093/annonc/mdz244.059 ↗
56. INNOVATE-3: phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer10.1200/JCO.2018.36.15_suppl.TPS5614 ↗
57. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study10.1016/j.ygyno.2018.07.018 ↗
58. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial10.1016/S1470-2045(14)70244-X ↗
59. Vergote I, NovoCure Ltd. Effect of tumor treating fields (TTFields, 200 kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (ENGOT-ov50/GOG-3029/INNOVATE-3) clinicalTrials.gov. Identifier (NCT number): NCT03940196. Available at: https://clinicaltrials.gov/ct2/history/NCT03940196?V_82=View#StudyPageTop.
60. Tumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase III INNOVATE-3/ENGOT-ov50 study. [abstract]. ESMO, Oct 2019
61. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies10.1038/nrclinonc.2015.53 ↗
62. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase II study10.1016/j.pan.2018.10.004 ↗
63. PANOVA-3 Study Investigators, Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase III PANOVA-3 study10.1200/JCO-25-00746 ↗
64. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
65. Tumor treating fields (TTFields) concomitant with sorafenib inhibit hepatocellular carcinoma in iitro and in vivo10.3390/cancers14122959 ↗
66. Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study10.3390/cancers14061568 ↗
67. HEPANOVA: final efficacy and safety results from a phase 2 study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC)
68. Electric field responsive nanotransducers for glioblastoma10.1186/s42234-022-00099-7 ↗
69. Tumor treating fields for glioblastoma: opportunities and drawbacks10.1080/17434440.2025.2526679 ↗
70. Tumor treating fields: a new frontier in cancer therapy10.1111/nyas.12112 ↗
71. Barium titanate nanoparticles sensitise treatment-resistant breast cancer cells to the antitumor action of tumour-treating fields10.1038/s41598-020-59445-x ↗
72. Transient turn-on characteristics of Si RBDT and SiC MOSFET under nanosecond current pulse range10.1016/j.sse.2024.108953 ↗
73. A SiC photo-conductive switch-based pulse generator with nanoseconds and high voltage for liver cancer cells ablation therapy10.3390/electronics13234816 ↗
74. High power nanosecond pulse laser driver using an GaN FET
75. TiO 2-coated electrodes for pulsed electric field treatment of microorganisms10.1109/TPS.2016.2571628 ↗
76. Ultrahigh-power-density BNT ferroelectric multilayer ceramic capacitors for pulse power energy conversion components10.1039/D4TC03279A ↗
77. Nanoparticles use magnetoelectricity to target and eradicate cancer cells
78. Nanosecond pulsed electric fields cause melanomas to self-destruct10.1016/j.bbrc.2006.02.181 ↗
79. Safety and efficacy of nanosecond pulsed electric field treatment of seborrheic keratoses., dermatologic surg off10.1097/DSS.0000000000002278 ↗
80. Optimized nanosecond pulsed electric field therapy can cause murine malignant melanomas to self-destruct with a single treatment10.1002/ijc.25364 ↗
81. Targeted gold nanorods combined with low-intensity nsPEFs enhance antimelanoma efficacy in vitro10.1088/1361-6528/ab925f ↗
82. Anti-tumor effects of nanosecond pulsed electric fields in a murine model of pancreatic cancer10.1016/j.bioelechem.2024.108803 ↗
83. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin10.1200/JCO.1991.9.3.389 ↗
84. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2. 16, ENGOT-Ov1, GCIG study10.1200/JCO.2017.73.4293 ↗
85. Update of randomized trials in recurrent disease10.1093/annonc/mdr518 ↗
86. Disruption of cancer cell replication by alternating electric fields10.1158/0008-5472.CAN-04-0083 ↗
87. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells10.1038/srep18046 ↗
88. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo10.1002/ijc.30406 ↗
89. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study10.1016/j.ygyno.2018.07.018 ↗
90. Nano‐pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases10.1002/ijc.31071 ↗
91. Microtubules as a target for anticancer drugs10.1038/nrc1317 ↗
92. Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis10.1038/onc.2008.82 ↗
93. Electrical based cancer therapy for solid tumours-theranostics approach
94. Schottky nanodiodes array enabled triboelectric nanosecond pulse generator for ultralow-cost tumor therapy10.1016/j.device.2025.100721 ↗
95. Nano‐pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases10.1002/ijc.31071 ↗
96. Long-term survival of mice with hepatocellular carcinoma after pulse power ablation with nanosecond pulsed electric fields10.7785/tcrt.2012.500237 ↗
97. Nanoelectroablation of murine tumors triggers a CD8-dependent inhibition of secondary tumor growth10.1371/journal.pone.0134364 ↗
98. Optimized nanosecond pulsed electric field therapy can cause murine malignant melanomas to self-destruct with a single treatment10.1002/ijc.25364 ↗
99. Nanosecond pulsed electric fields as a novel drug free therapy for breast cancer: an in vivo study10.1016/j.canlet.2013.09.032 ↗
100. A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields10.1016/j.ejca.2014.07.006 ↗